Large companies often focus R&D on high-ticket items, neglecting smaller accessory categories. This creates a market gap for focused startups to innovate and solve specific problems that bigger players overlook, allowing them to build a defensible niche.

Mechanization made bagels a mainstream, mass-produced item, often leading to a lower-quality product. This widespread commoditization paradoxically opened a high-end niche. Consumers, familiar with the basic concept, became willing to pay a premium for superior, artisanal versions, fueling the rise of chains selling bagels for over $3 each.

The founder of robotics company Matic discovered a hard ceiling for consumer adoption. Their product saw "organ rejection" at $1,500 and only found traction under $1,000. This suggests there are virtually no ubiquitous consumer electronics devices priced over $2,000, a significant challenge for expensive hardware like humanoid robots.

Formula One heavily restricts and penalizes teams for using traditional wind tunnels to control costs. This regulatory pressure created the perfect market opening for Skin Systems' cheaper, more effective "smart tape" solution, which circumvents these expensive, time-limited resources.

When launching an innovative product, the cost of educating consumers is a direct hit to margins. Many great products fail not because they are inferior, but because the expense of explaining their value is too high to sustain profitability, a concept described as "education eats margins."

Major product breakthroughs often come from solving a problem for a niche group with extreme needs. The solution developed for this 'extreme user' can then be adapted and applied to a much broader general population, creating a significant market opportunity.

Innovation naturally starts as an expensive product for the wealthy before economies of scale make it affordable for all. Society 'glitches' by demanding government intervention for equal access during the expensive initial phase, which short-circuits the very market process that would have eventually made it cheap and ubiquitous.

Many MedTech companies mistakenly believe a clinically superior product will automatically win market share. This is false. Market adoption is not automatic; it must be designed as intentionally as the product itself to overcome the powerful inertia of the status quo and make the market mentally ready for change.

For expensive physical products where rapid software-style iteration is impossible, conduct single-unit pilots in adjacent or smaller markets. This allows for crucial design optimization and learning without the high cost and risk of failing in your primary target market before you're ready to scale.